Christopher G Kanakry
National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christopher G Kanakry as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:20 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07162038 · Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell TransplantationNational Cancer Institute (NCI) · recruiting · Hematologic Malignancies, Hematologic Neoplasms · principal investigator
- N/ANCT06856226 · Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell TransplantNational Cancer Institute (NCI) · recruiting · Leukemia, Lymphoma, Hematologic Malignancy · principal investigator
- Ph1/Ph2NCT05436418 · The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell TransplantationNational Cancer Institute (NCI) · recruiting · Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation · principal investigator
- Ph1/Ph2NCT05327023 · Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic MalignanciesNational Cancer Institute (NCI) · recruiting · Hematologic Neoplasms · principal investigator
- Ph1/Ph2NCT04959175 · Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic MalignanciesNational Cancer Institute (NCI) · recruiting · Hematologic Neoplasms · principal investigator
- Ph1/Ph2NCT03983850 · Optimizing PTCy Dose and TimingNational Cancer Institute (NCI) · active not recruiting · Graft Versus Host Disease, Hematologic Neoplasms · principal investigator
- Ph2NCT01338987 · Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow TransplantationNational Cancer Institute (NCI) · completed · Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Deciphering the efficacy of posttransplant cyclophosphamide in BMTZIABC011659 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2015 to 2025 · $3,453,330 awarded in 2025Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:20 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- 242 citationsRCR 7.5
- Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis.Blood · 2021175 citationsRCR 12.7
- 87 citationsRCR 6.9
- Prospective Study of a Novel, Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform for Primary Immunodeficiency Diseases.Biol Blood Marrow Transplant · 202044 citationsRCR 2.2
- Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation.Blood Adv · 202529 citationsRCR 9.0
- Outcomes of Related and Unrelated Donor Searches Among Patients with Primary Immunodeficiency Diseases Referred for Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant · 201916 citationsRCR 0.7
- Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study.Lancet Haematol · 201815 citationsRCR 0.7
- 18F-FLT PET and Blood-based Biomarkers for Identifying Gastrointestinal Graft versus Host Disease after Allogeneic Cell Transplantation.Radiol Imaging Cancer · 20252 citationsRCR 0.4